Growth Metrics

Invivyd (IVVD) Liabilities and Shareholders Equity (2020 - 2025)

Invivyd posted quarterly Liabilities and Shareholders Equity of $276.9 million for Q4 2025, up 113.78% year-on-year from $129.5 million in Q4 2024, and up 98.97% on a QoQ basis from $139.2 million in Q3 2025.

Invivyd (IVVD) has 6 years of Liabilities and Shareholders Equity data on file, last reported at $276.9 million in Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 113.78% year-over-year to $276.9 million; the trailing twelve-month figure through Dec 2025 stood at $608.9 million (down 11.01% YoY), and the FY2025 full-year result was $276.9 million, up 113.78% from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 stood at $276.9 million, up from $139.2 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $686.3 million in Q3 2021 and bottomed at $89.1 million in Q2 2025.
  • The 5-year median for Liabilities and Shareholders Equity is $276.9 million (2025), against an average of $316.7 million.
  • The widest annual swing landed in 2021, when Liabilities and Shareholders Equity jumped 428.27%; it then slumped 51.85% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $620.1 million in 2021, then plunged by 38.21% to $383.2 million in 2022, then tumbled by 40.19% to $229.2 million in 2023, then plunged by 43.49% to $129.5 million in 2024, then jumped by 113.78% to $276.9 million in 2025.
  • The last three Liabilities and Shareholders Equity figures came in at $276.9 million (Q4 2025), $139.2 million (Q3 2025), and $89.1 million (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 14.93 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 37.37 Mn
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 1.73 Bn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 78.88 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 33.89 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 26.48 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - 23.64 Mn
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 40.87 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 5.13 Bn
10 Invivyd 208.38 Mn -18.31 Mn - 276.88 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 276.88 Mn
Sep 30, 2025 139.16 Mn
Jun 30, 2025 89.14 Mn
Mar 31, 2025 103.74 Mn
Dec 31, 2024 129.52 Mn
Sep 30, 2024 161.92 Mn
Jun 30, 2024 177.35 Mn
Mar 31, 2024 215.47 Mn
Dec 31, 2023 229.18 Mn
Sep 30, 2023 274.92 Mn
Jun 30, 2023 315.41 Mn
Mar 31, 2023 350.56 Mn
Dec 31, 2022 383.17 Mn
Sep 30, 2022 424.75 Mn
Jun 30, 2022 484.61 Mn
Mar 31, 2022 556.27 Mn
Dec 31, 2021 620.09 Mn
Sep 30, 2021 686.27 Mn
Jun 30, 2021 397.99 Mn
Dec 31, 2020 117.38 Mn